Free Trial
→ Trump’s betrayal exposed (From Porter & Company) (Ad)tc pixel

Genmab A/S (OTCMKTS:GNMSF) Shares Cross Above Fifty Day Moving Average - Time to Sell?

Written by MarketBeat
Updated August 31, 2025
Genmab A/S logo with Medical background

Key Points

  • Genmab A/S (OTCMKTS:GNMSF) saw its stock price rise above its 50-day moving average of $218.00, reaching a high of $245.00 during trading.
  • The company reported $5.42 EPS for the latest quarter, surpassing estimates by $1.43, although revenue of $925 million fell short of expectations.
  • Genmab A/S has a market cap of $16.19 billion and a PE ratio of 12.30, indicating its valuation and investor sentiment towards its future earnings growth.
  • Five stocks we like better than Genmab A/S.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report)'s share price passed above its fifty day moving average during trading on Monday . The stock has a fifty day moving average of $218.00 and traded as high as $245.00. Genmab A/S shares last traded at $245.00, with a volume of 32 shares.

Genmab A/S Stock Up 0.3%

The stock has a market cap of $16.47 billion, a price-to-earnings ratio of 12.51 and a beta of 0.90. The company's 50-day simple moving average is $220.49 and its 200-day simple moving average is $210.84.

Genmab A/S (OTCMKTS:GNMSF - Get Free Report) last posted its quarterly earnings data on Thursday, August 7th. The company reported $5.42 earnings per share for the quarter, topping the consensus estimate of $3.99 by $1.43. Genmab A/S had a net margin of 37.53% and a return on equity of 21.03%. The firm had revenue of $925.00 million for the quarter, compared to analysts' expectations of $949.06 million.

About Genmab A/S

(Get Free Report)

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC.

Read More

Should You Invest $1,000 in Genmab A/S Right Now?

Before you consider Genmab A/S, you'll want to hear this.

MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Genmab A/S wasn't on the list.

While Genmab A/S currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.

View The Five Stocks Here

7 Energy Stocks to Buy and Hold Forever Cover
7 Energy Stocks to Buy and Hold Forever

With the proliferation of data centers and electric vehicles, the electric grid will only get more strained. Download this report to learn how energy stocks can play a role in your portfolio as the global demand for energy continues to grow.

Get This Free Report
Like this article? Share it with a colleague.